Nutra Pharma Corporation: Nutra Pharma Engages Quality and Regulatory Professionals Ahead of Clinical Trials
Nutra Pharma is providing updates on their work in improving capabilities and certifications in their laboratory for drug production and validation in preparation of expanded OTC sales and clinical trials
Plantation, Florida--(Newsfile Corp. - March 11, 2021) - Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, is providing updates today on their work in improving their existing facilities for manufacturing and validation of their drug products; including their technologies for the treatment of Multiple Sclerosis (MS) and potential countermeasures against nerve agents like sarin gas and VX. As part of this process, Nutra Pharma today announces the engagement of AccuReg, Inc. as outside Regulatory and Quality Assurance consultants.